Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Epalrestat - ≥97%, high purity , Aldose reductase inhibitor, CAS No.82159-09-9, Aldose reductase inhibitor

Specifications & Purity:  ≥97%
Item Number
E129897
Grouped product items
SKUSizeAvailabilityPrice Qty
E129897-1g
1g
In stock
$111.90
E129897-5g
5g
In stock
$278.90
E129897-25g
25g
In stock
$1,252.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET

Potent aldose reductase inhibitor

View related series
CYP4A11 Inhibitor

Basic Description

Synonymsepalrestat|82159-09-9|Kinedak|Epalrestatum|Epalrestat [INN]|Ono 2235|Ono-2235|2-((z)-5-((e)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid|Aldonil|Aldorin|Tanglin|2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanyli
Specifications & Purity≥97%
Storage TempStore at -20°C
Shipped InDry ice
Action TypeINHIBITOR
Mechanism of actionAldose reductase inhibitor

Product Properties

ALogP3.8

Associated Targets

CYP4A11 Tbio Cytochrome P450 4A11 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKR1B10 Tchem Aldo-keto reductase family 1 member B10 4 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKR1B1 Tclin Aldose reductase 11 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
INCHI InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
InChi Key CHNUOJQWGUIOLD-NFZZJPOKSA-N
Canonical SMILES CC(=CC1=CC=CC=C1)C=C2C(=O)N(C(=S)S2)CC(=O)O
Isomeric SMILES C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O
WGK Germany 3
PubChem CID 1549120
Molecular Weight 319.4

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

4 results found

Lot NumberCertificate TypeDateItem
J1930145Certificate of AnalysisJun 07, 2023 E129897
F2316138Certificate of AnalysisMay 09, 2023 E129897
G2117224Certificate of AnalysisMay 09, 2023 E129897
G2117225Certificate of AnalysisMay 09, 2023 E129897

Chemical and Physical Properties

SolubilityDMSO 2 mg/mL Water <1 mg/mL Ethanol <1 mg/mL
Melt Point(°C)224 °C

Safety and Hazards(GHS)

Pictogram(s) GHS06,GHS07
Signal Danger
Hazard Statements H315,H319,H335,H300
Precautionary Statements P261,P305+P351+P338,P280,P302+P352,P321,P405,P501,P264,P271,P270,P304+P340,P403+P233,P362+P364,P330,P264+P265,P301+P316,P337+P317,P332+P317,P319
WGK Germany 3
Merck Index 3605

Related Documents

 SDS

 Specification Sheet

References

1. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N et al..  (2006)  Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial..  Diabetes Care,  29  (7): (1538-44).  [PMID:16801576]
2. Ramirez MA, Borja NL.  (2008)  Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy..  Pharmacotherapy,  28  (5): (646-55).  [PMID:18447661]
3. Ji J, Xu MX, Qian TY, Zhu SZ, Jiang F, Liu ZX, Xu WS, Zhou J, Xiao MB.  (2020)  The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer..  Mol Biol Rep,  47  (8): (6091-6103).  [PMID:32761301]
4. Geng N, Jin Y, Li Y, Zhu S, Bai H.  (2020)  AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma..  Int J Med Sci,  17  (9): (1246-1256).  [PMID:32547320]
5. Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y, Terashima H, Morimura T, Tsuboshima M.  (1983)  Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats..  Diabetologia,  24  (4): (290-2).  [PMID:6407887]
6. Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y.  (1984)  Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats..  Metabolism,  33  (3): (212-4).  [PMID:6420645]
7. Takahashi M, Fujii J, Miyoshi E, Hoshi A, Taniguchi N.  (1995)  Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes..  Int J Cancer,  62  (6): (749-54).  [PMID:7558425]
8. Yamaori S, Araki N, Shionoiri M, Ikehata K, Kamijo S, Ohmori S, Watanabe K.  (2018)  A Specific Probe Substrate for Evaluation of CYP4A11 Activity in Human Tissue Microsomes and a Highly Selective CYP4A11 Inhibitor: Luciferin-4A and Epalrestat..  J Pharmacol Exp Ther,  366  (3): (446-457).  [PMID:29976573]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.